Home » Trade Groups Urge FDA to Re-examine Off-Label Standards
Trade Groups Urge FDA to Re-examine Off-Label Standards
Industry trade group giants, PhRMA and BIO are nudging FDA to re-examine how it regulates off-label communication between drugmakers, health-care providers and payers.
PhRMA and BIO jointly published a set of principles covering what they believe drugmakers should and should not be allowed to share with doctors, insurance companies and pharmacy benefit managers. The FDA’s rules governing off-label information exchanges — which are intended to limit off-label promotion — are frequently challenged by industry on First Amendment grounds.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May